Skip to main content
SpringerLink
Log in

ASH 2015: Von der Jahrestagung der amerikanischen Hämatologen

Orlando, 05.–08. Dezember 2015

ASH Annual Meeting 2015

Orlando, December 5 to 8

  • Onkologiekongresse
  • Published:
Der Onkologe Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3

Literatur

  1. Kochenderfer JN et al (2015) Allogeneic T‑cells expressing an anti-CD19 chimeric antigen receptor cause remissions of B‑cell malignancies that progress after allogeneic hematopoietic stem cell transplantation without causing graft-versus-host disease. ASH (abstr 99)

  2. Kochenderfer JN et al (2015) Remissions of Multiple Myeloma during a First-in-Humans Clinical Trial of T Cells Expressing an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor. ASH (abstr. LBA-1)

  3. Cserti-Gazdewich C et al (2015) Tissue oxygenation by transfusion in severe anemia with lactic acidosis (TOTAL): a prospective, randomized, non-inferiority trial of blood storage duration. ASH (abstr 769)

  4. Chai-Adisaksopha C et al (2015) Switching to warfarin after 6‑month completion of anticoagulant treatment for cancer-associated thrombosis. ASH (abstr 430)

  5. Stone RM et al: The Multi-Kinase Inhibitor Midostaurin(M) Prolongs Survival Compared with Placebo (P) in Combination with Daunorubicin (D)/Cytarabine(C) Induction (ind), High-Dose C Consolidation (consol), and as Maintenance (maint) Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients (pts) Age 18–60 with FLT3 Mutations (muts): An International Prospective Randomized (rand) P‑Controlled Double-Blind Trial. ASH 2015 (abstr 6)

  6. Maury S et al (2015) Addition of rituximab improves the outcome of adult patients with CD20-positive, Ph-negative, B‑cell precursor acute lymphoblastic leukemia. ASH (Plenary Session, abstr 1)

  7. Moreau P et al (2015) Ixazomib, an Oral Proteasome Inhibitor, in Combination with Lenalidomide and Dexamethasone (IRd), Significantly Extends Progression-Free Survival for Patients with Relapsed and/or Refractory Multiple Myeloma: The Phase 3 TOURMALINE-MM1 Study (NCT01564537). ASH (abstr 727)

  8. Tedeschi A et al (2015) Results from the international, randomized phase 3 study of Ibrutinib versus chlorambucil in patients 65 years and older with treatment-naïve CLL/SLL (RESONATE-2TM). ASH (abstract 495)

  9. Zelenetz AD et al (2015) Idelalisib plus bendamustine and rituximab (BR) is superior to BR alone in patients with relapsed/refractory chronic lymphocytic leukemia: results of a phase 3 randomized double-blind placebo-controlled study. ASH (abstract LBA-5)

  10. Stilgenbauer S et al (2015) Venetoclax(ABT-199/GDC-0199) Monotherapy Induces Deep Remissions, Including Complete Remission and Undetectable MRD, in Ultra-High Risk Relapsed/Refractory Chronic Lymphocytic Leukemia with 17p Deletion: Results of the Pivotal International Phase II Study. ASH (abstract LBA-6)

Download references

Author information

Authors and Affiliations

  1. Sellscheid 100, 42929, Wermelskirchen, Deutschland

    A. Junker

Authors
  1. A. Junker
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Junker.

Ethics declarations

Interessenkonflikt

A. Junker gibt an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Junker, A. ASH 2015: Von der Jahrestagung der amerikanischen Hämatologen. Onkologe 22, 206–211 (2016). https://doi.org/10.1007/s00761-016-0025-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00761-016-0025-5

Search

Navigation